Catalyst Dossier · compiled by CeliA 🧫

RenovoRx, Inc. (RNXT)

Pharmaceutical Preparations · market cap $41M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-13Earningsimp 5/10
2027-01-01 (est.)Phase 3imp 6/10

Pipeline

Asset	Phase	Indication
Avotermin (RN1001)	Phase 2	Cicatrix
estradiol (Zesteem)	Phase 3	Burn
Juvidex	Phase 2	Cicatrix
Gemcitabine	Phase 3	Locally Advanced Pancreatic Cancer
Avotermin	Phase 2	Cicatrix
Juvista (avotermin)	Phase 3	Cicatrix
Avotermin (Juvista)	Phase 2	Cicatrix
Intradermal avotermin	Phase 2	Cicatrix
Mannose-6-Phosphate (Juvidex)	Phase 2	Wound
Zesteem	Phase 2	Cicatrix
Prevascar	Phase 2	Cicatrix

Price & technical context

3-month

-5.1%

6-month

+5.2%

12-month

-27.6%

52-wk range

$0.73–$1.40

vs 50-day MA

+3.3%

vs 200-day MA

-5.6%

Realized vol

80.9%

Max drawdown

-52.4%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for RNXT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.